1. Home
  2. KYNB vs DYAI Comparison

KYNB vs DYAI Comparison

Compare KYNB & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$7.31

Market Cap

27.1M

Sector

Health Care

ML Signal

N/A

Logo Dyadic International Inc.

DYAI

Dyadic International Inc.

HOLD

Current Price

$1.21

Market Cap

32.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KYNB
DYAI
Founded
1993
1979
Country
United States
United States
Employees
34
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
32.5M
IPO Year
N/A
2003

Fundamental Metrics

Financial Performance
Metric
KYNB
DYAI
Price
$7.31
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
15.6K
248.7K
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,090,345.00
Revenue This Year
N/A
$122.79
Revenue Next Year
N/A
$100.00
P/E Ratio
$0.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.32
$0.65
52 Week High
$9.58
$1.35

Technical Indicators

Market Signals
Indicator
KYNB
DYAI
Relative Strength Index (RSI) 54.14 68.08
Support Level $6.59 $0.76
Resistance Level $7.41 $1.29
Average True Range (ATR) 0.30 0.11
MACD -0.01 0.02
Stochastic Oscillator 53.68 71.45

Price Performance

Historical Comparison
KYNB
DYAI

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

About DYAI Dyadic International Inc.

Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Share on Social Networks: